Images of Romance Valentine’s Day brings up images of romance. Have you been afraid to be intimate with your loved one because you may become short of breath? Your idea of being sexually attractive does not include having a cannula on your face? No fear, we are going to give you lessons! We like how…
Portable Oxygen Concentrators Note: Please consult with your doctor or therapist before deciding to use or purchase any of these devices. Intermittent Flow POCs (IF POCs) AirSep® LifeChoice® AirSep® One® G2 Inogen Lifestyle™ Inova Labs XPO2™ Invacare® Freestyle™ Flow Settings Available Settings 1 to 3 1 to 5 1 to 5 1 to 3…
Nutritional Education for Pulmonary Patients This article was prepared by Sue Lutz MS, RD, LD/N, Florida Hospital Memorial Medical Center, Ormond Beach, FL. ood nutrition is important to keep you healthy. A well-balanced diet gives your body the nutrients it needs for energy, maintaining body cells and regulating body processes. It may be helpful to…
Spread the Word about Augmentation Therapy for Alpha-1! Alpha-1 is the genetic form of emphysema caused by a lack of a protein in the blood. Even though augmentation (or re- placement) therapy has been available for 25 years, a small fraction of those with Alpha-1 emphyse- ma receive the therapy. It involves…
Restrictive (as Pulmonary Fibrosis) vs.Obstructive Disease (COPD) Although there are hundreds of diseases that can affect the lungs, we do broadly describe almost all lung disease as either restrictive or obstructive. The obstructive group of diseases, primarily emphysema and chronic bronchitis, are also known as Chronic Obstructive Pulmonary Disease or COPD. It wasn’t that long…
Portable Oxygen Concentrator Update In the January 2000 issue of Respiratory Care, Dr. Tom Petty stated that, “Practical portable concentrators should weigh no more than 10 pounds, produce 90% or more oxygen, and provide at least 2L of oxygen for a minimum of 4 hours.” Within two years, the first modern portable oxygen concentrator (POC)…
Respiratory News Researchers from New York’s Mount Sinai have partnered with Theragene Pharmaceuticals to further develop a new airway-delivered gene therapy for pulmo- nary hypertension. After showing prom- ising results in animal studies, this new therapy will advance to clinical trials, which are expected to take place in the next two years. If…